An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumab.
Wien Med Wochenschr. 2022 Nov;172(15-16):359-364. doi: 10.1007/s10354-022-00939-w. Epub 2022 Jun 20.
Wien Med Wochenschr. 2022.
PMID: 35723820
Free PMC article.
Review.